Orum Therapeutics has dosed the first subject in a Phase I clinical trial of the drug candidate ORM-5029 for HER2-expressing advanced solid tumour patients.

The multicentre, open-label, dose escalation, and expansion trial will analyse ORM-5029 in HER2-expressing advanced solid tumour patients who are not eligible to receive standard-of-care treatment.

It will evaluate the safety, pharmacokinetics, and initial anti-tumour activity of ORM-5029 given as intravenous doses.

Through antibody targeting, ORM-5029 offers catalytic GSPT1 protein degraders to HER2-expressing tumour cells. 

It is one of two lead programmes using Orum’s GSPT1 platform that utilises the Dual-Precision Targeted Protein Degradation (TPD²) approach.

This method uses antibody drug conjugates (ADCs) to accurately deliver and act on intracellular proteins for degradation causing the death of cancer cells.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

For ORM-5029, the company developed a class of GSPT1 degrader molecules and combined them with pertuzumab, a HER2-targeting antibody. It then analysed various candidate conjugates to detect a molecule with the preferred therapeutic profile.

In preclinical research, ORM-5029 showed strong potency in vitro and in vivo in low-HER2 settings, as well as dose-dependent efficacy as against small molecule GSPT1 degraders or standard-of-care ADCs.

Orum Therapeutics CEO Sung Joo Lee said: “The initiation of this clinical trial represents a series of firsts for Orum, it’s our first drug candidate from our GSPT1 degrader conjugate platform to enter the clinic, and ORM-5029 is a first-in-class molecule that represents a novel approach to precision targeted protein degraders.

“In addition to ORM-5029, we are harnessing the power of various protein degraders with the precision of antibodies, with the potential to improve the treatment of cancer for more patients.”